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Letters to the Editor 
Dear Editor 
Bronchoconstriction following inhaled ethanol 
solutions 
We wish to report two cases of bronchoconstric- 
tion, following inhalation of ethanol solutions in 
asthmatic patients, from a total of five patients 
studied prior to early termination of a clinical inves- 
tigation. Both patients were mild asthmatics, and 
their condition was normally controlled by inhaled 
bronchodilators alone. 
As part of a programme of exploratory work 
looking at various potential agents for asthma 
therapy, we conducted a single blind cross-over 
study to examine the effects on respiratory function 
of two solutions (10 and 20%) of inhaled ethanol, 
used as a drug solubilizing medium. The protocol 
specified that patients would be withdrawn from the 
study day if their forced expiratory volume in 1 s 
(FEV,) fell to 85% of its baseline value, and with- 
drawn from the entire study if the FEV, fell to 70% 
of baseline. 
CASE 1 
A 24-year-old female with mild stable asthma, 
FEV, 3.01 1 on entry (108% predicted), inhaled 
ascending doses at 15-min intervals of a 20% ethanol 
solution. Fifty microlitres, 100,~1, 150 ,~l and 200~1 
were all well tolerated without a fall in FEV,. Five 
minutes following a 250~1 dose, FEV, fell to 2.48 1 
(82.4% of entry value) and continued to fall, reaching 
1.81 1 (60.1% of entry value) at 41 min post-dosing 
despite administration of inhaled salbutamol(200 pug) 
(Fig. 1). Recovery followed a nebulized dose of 
salbutamol (5 mg). A 10% ethanol solution had 
previously been well tolerated at all doses. 
CASE 2 
A 27-year-old male with mild stable asthma, FEV, 
4.05 1 on entry (97% predicted), inhaled ascending 
doses at 15 min intervals of a 10% ethanol solution, 
having previously tolerated 5 ascending doses of a 
20% solution. Immediately following the initial dose 
of 10% solution, FEV, fell slightly and continued to 
fall over the next 10 min reaching 3.68 1 (90.9% of 
entry value). A 100,~l dose was then inhaled, the 
FEV, fell further to 3.38 1(83.5% of entry value). He 
0954-611 l/95/060457 +02 $08.00/O 
U 1 2 
Time post-dose (h) 
Fig. I Course of bronchoconstriction (Case 1) following 
dosing with ethanol solution (250,~l). 
was given inhaled salbutamol (200 pug) and recovered 
rapidly. 
A number of previous case reports (1,2) have also 
observed this phenomenon, although in a separate 
study (3), 10 ml of a nebulized 40% ethanol solution 
did not cause bronchospasm. Some pressurized 
metered dose inhaler formulations, chiefly those 
available in North America, contain ethanol and are 
presumably tolerated by the majority of asthmatics. 
Bronchoconstriction can be caused by preservatives 
in nebulizer solutions, and by solution pH or tonicity 
(4), and can also arise as a result of deep inhalations 
associated with repeat lung function testing (5). How- 
ever, our observations suggest that bronchoconstric- 
tion following inhaled ethanol solutions may be 
an unpredictable and potentially serious hazard in 
susceptible individuals, and that such solutions 
should only be given with caution. 
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Dear Editor 
Non-tuberculons Mycobacteria 
The informative paper by Hosker et al. (1) on the 
prevalence of ‘pulmonary infection due to non- 
tuberculous mycobacteria’ in Hong Kong provides 
an occasion for drawing attention to the verbal 
confusions arising from the illogical decision to adopt 
the specific name ‘tuberculosis’ for the species of 
mycobacterium most commonly associated with 
tuberculosis in the human subject. In colloquial dis- 
course, this organism has been called the human 
tubercle bacillus with clarity and propriety, and it 
is regrettable that this term was not translated 
into Latin as Mycobacterium hominis in the formal 
terminology of the mycobacteria. 
We should not confuse a disease with its own 
cause. ‘Tuberculosis’ currently refers to a disease 
characterized by granulomatous changes caused by a 
mycobacterium. This diagnosis places the patient in a 
category with defining characteristics in two fields, 
morbid anatomy and aetiology. A complete diag- 
nostic statement would include identification of the 
causal mycobacterium. When a diagnosis of tubercu- 
losis, unspecified, is made in man it is implied that the 
causal organism is thought, or has been shown, to be 
the human tubercle bacillus. In the days when disease 
caused by Mycobacterium bovis was important in 
man, it was referred to as bovine tuberculosis, imply- 
ing with perfect clarity a disease caused by the species 
of mycobacterium most commonly causing disease in 
cattle. The adoption of the name hominis for the 
species most prevalent in the human race would have 
been logical and convenient, and would not have 
implied that only the disease caused by this species is 
properly called tuberculosis in man, leaving granulo- 
matous diseases caused in man by other species of 
mycobacteria in limbo (2). 
With this terminology, the phrase ‘Pulmonary 
infection by mycobacteria other than M. hominis’ 
would have indicated clearly the subject of the Hong 
Kong paper without suggesting that some other 
name should be found for morbid-anatomical 
tuberculosis caused by other species of mycobacteria. 
J. G. SCADDING 
Emeritus Professor of Medicine 
6 February 1995 
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Reply to Prof Scadding 
We thank Professor Scadding for his interest in 
our work and share his concerns regarding the 
confusion regarding terminology for Mycobacterial 
disease. 
Our use of the term non-tuberculous mycobacteria 
was chosen as the one most widely used at the 
present time to describe Mycobacteria, other than 
Mycobacterium tuberculosis. 
We look forward to the time when a definitive 
terminology is agreed by all scientists and clinicians. 
H. S. R. HOSKER 
Department of Respiratory Medicine 
Burnley Health Care NHS Trust 
Pendle Community Hospital 
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